Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-03-23 08:20 |
Pharming Group announces the intention to nominate three Non-Executive Director…
|
English | 180.5 KB | ||
| 2021-03-16 14:20 |
Pharming Group to present at 31st Annual Oppenheimer Healthcare Conference
|
English | 132.4 KB | ||
| 2021-03-11 08:32 |
Pharming Group to Present at BioCapital Europe 2021
|
English | 132.7 KB | ||
| 2021-03-04 08:32 |
Pharming Group reports financial results for full year 2020
|
English | 187.8 KB | ||
| 2021-03-02 08:27 |
Pharming Group, in collaboration with Invitae Corporation, launches genetic tes…
|
English | 182.9 KB | ||
| 2020-12-23 15:06 |
Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol "PHA…
|
English | 66.9 KB | ||
| 2020-12-23 15:05 |
Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasd…
|
English | 71.6 KB | ||
| 2020-11-23 08:10 |
Juergen Ernst to retire from Pharming’s Board of Supervisory Directors after mo…
|
English | 112.0 KB | ||
| 2020-11-19 08:23 |
Pharming announces commitment to build a new downstream manufacturing facility …
|
English | 110.7 KB | ||
| 2020-11-09 08:19 |
Pharming appoints Jeroen Wakkerman as Chief Financial Officer
|
English | 113.8 KB | ||
| 2020-10-29 08:18 |
Pharming Group reports financial results for the first nine months of 2020
|
English | 193.8 KB | ||
| 2020-10-29 08:18 |
Pharming convenes Extraordinary General Meeting of shareholders
|
English | 111.8 KB | ||
| 2020-10-21 08:31 |
Pharming receives Orphan Drug Designation from the European Commission for leni…
|
English | 32.7 KB | ||
| 2020-08-17 09:28 |
Pharming announces the publication of data from a compassionate use programme o…
|
English | 107.4 KB | ||
| 2020-08-10 08:08 |
Pharming announces enrolment of first patient in multinational clinical trial f…
|
English | 113.8 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
